Pharming PHAR
NASDAQ PHAR
$13.22 +0.06 (+0.46%)
At close: Nov 10, 2026 · 4:00 PM EST

Pharming (PHAR) Accumulated Expenses (2021 - 2024)

Updated

Pharming (PHAR) posted Accumulated Expenses of $4.15 million for Q4 2023, up 104.9% from $2.03 million a year earlier.

Analysis

Pharming (PHAR) Accumulated Expenses (2021 - 2024) Analysis & Trends

  • In prior years, Pharming's Accumulated Expenses was $2.03 million in FY2022 (-11.5%) and $2.29 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Pharming 927.62 Mn 229.29 Mn 102.20
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 4.02 Mn
Dec 31, 2023 4.15 Mn
Dec 31, 2022 2.03 Mn
Dec 31, 2021 2.29 Mn
API Access

Pharming Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=PHAR&period=max&api_key=YOUR_API_KEY